A molecule can be studied in an animal and in a human brain model using the same service provider. This is the technology that OrganoTherapeutics brings to its new owner. Transpharmation announced, on Wednesday 28 October, the acquisition of the Luxembourg-based biotech company. The value of the deal has not been disclosed. The buyer has not provided further details on the stake acquired or the identity of the sellers.
OrganoTherapeutics develops brain organoids and assembloids. These three-dimensional structures are grown from human stem cells, including those derived from patients. They are not complete miniature brains. They replicate certain cells, regions and characteristics of the brain in order to study a disease or the response to a molecule. The spin-off has developed models for Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and other neurodegenerative conditions. It works with pharmaceutical and biotechnology companies in Europe, the United States and Asia.
A new round of tests
Transpharmation has historically developed its expertise in in vivo studies, i.e. studies involving animals. The group carries out preclinical research for pharmaceutical companies in the fields of neuroscience, pain and metabolic diseases. This work takes place before a potential treatment can be administered to patients.
OrganoTherapeutics offers a second approach, based on human cells. Clients will be able to use both animal models and organoids from the same group. This will enable them to verify at an earlier stage whether the effects observed using the first method are replicated using the second.
“We see a clear future for the company in providing non-animal models, alongside our preclinical pharmacology,” says Mark Duxon, CEO of Transpharmation. He describes the acquisition as a first step towards building a portfolio that incorporates human tissues and systems.
The stated aim is, therefore, not to abolish animal testing immediately. Transpharmation aims to bridge the gap between the two methods in order to better predict the action and efficacy of a drug candidate prior to clinical trials. Clinical trials require more time and money and directly expose human participants to risk.
The Luxembourg section will remain… in Luxembourg
“Over the past few years, we have developed models of human brain organoids and assembloids derived from induced pluripotent stem cells for Parkinson’s and Huntington’s diseases, amyotrophic lateral sclerosis and other neurodegenerative diseases, and we have used them in numerous studies for pharmaceutical and biotechnology partners,” explains Jens Schwamborn, cofounder of OrganoTherapeutics.
The researcher believes that the two companies will be able to offer “both approaches under one roof” and help their clients make better decisions earlier on in the drug development process.
OrganoTherapeutics will continue to operate as a subsidiary. Its entire team will remain in Luxembourg. The business will continue to be based at the House of BioHealth in Esch-sur-Alzette. The biotech company also states that its research into human brain models will remain unchanged.
Founded in 2019, the company grew out of the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg. Jens Schwamborn and Javier Jarazo were still at the helm when the 2025 accounts were finalised. The company generated a turnover of €595,333 in 2025. It had recorded €1.19m in 2024. Its profit fell from €615,995 to €169,520. Its average workforce increased from 3.68 to 4.94 full-time equivalents. The company publicly presented a team of seven people at the start of 2026.
Prior to the transaction, OrganoTherapeutics was owned by Jens Schwamborn (42.27%), Javier Jarazo (42.27%), Silvia Bolognin (9.39%) and the German fund Khan-I (6.07%). This breakdown is set out in a notarial deed dated 25 August 2025. It does not provide information on the shareholding structure following the takeover.
Transpharmation is legally a British company, incorporated in 2010. However, it belongs to a transatlantic group centred on the Canadian firm Vivocore, which acquired the British company in 2021. The group operates in Canada, the United Kingdom, Poland and Ireland. It reported having more than 150 employees in 2025.
The acquisition of OrganoTherapeutics is part of an ongoing strategy to expand the company’s technological capabilities. In April 2025, Transpharmation had already acquired the British company Saretius, which specialises in disease models and biomarkers. With the human brain models developed in Esch-sur-Alzette, the group is now seeking to bridge the gap between laboratory results and the responses observed in patients.


